CombiChem Outside Collaborations May End After Purchase By DuPont
Executive Summary
The future of CombiChem's existing collaborations is uncertain following DuPont's announcement that it will acquire the company for approximately $95 mil.
You may also be interested in...
Oral IIb/IIIa Antiplatelet Development Winding Down; Four Companies Out
Eight clinical development programs for oral glycoprotein IIb/IIIa receptor antagonists are being closed down in response to lack of compound efficacy.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials